Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers, announced updated data from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. The data cutoff was August 18, 2026, for the 5.4 mg/kg dose cap population. MICVO demonstrated a confirmed objective response rate of 36% and a disease control rate of 94%. Median progression-free survival was 6.2 months, with a 12-month overall survival probability of 79%. No new safety signals were observed, though peripheral neuropathy occurred in 40% of patients. The company plans to initiate a pivotal Phase 3 trial in mid-2027.
